Vanda Pharmaceuticals Inc.VNDAEarnings & Financial Report
Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies for central nervous system disorders. Its key marketed products cover indications including sleep-wake cycle disturbances and schizophrenia, with core operations and primary sales markets concentrated in North America, catering to patient groups with significant unmet medical needs.
VNDA Q4 FY2025 Key Financial Metrics
Revenue
$57.2M
Gross Profit
N/A
Operating Profit
$-40.4M
Net Profit
$-141.2M
Gross Margin
N/A
Operating Margin
-70.5%
Net Margin
-246.8%
YoY Growth
7.6%
EPS
$-2.40
Vanda Pharmaceuticals Inc. Q4 FY2025 Financial Summary
Vanda Pharmaceuticals Inc. reported revenue of $57.2M (up 7.6% YoY) for Q4 FY2025, with a net profit of $-141.2M (down 2774.3% YoY) (-246.8% margin).
Key Financial Metrics
| Total Revenue | $57.2M |
|---|---|
| Net Profit | $-141.2M |
| Gross Margin | N/A |
| Operating Margin | -70.5% |
| Report Period | Q4 FY2025 |
Revenue Breakdown
Vanda Pharmaceuticals Inc. Q4 FY2025 revenue of $57.2M breaks down across 3 segments, led by Fanapt at $33.2M (58.1% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Fanapt | $33.2M | 58.1% |
| Hetlioz | $16.4M | 28.6% |
| PONVORY | $7.6M | 13.3% |
Vanda Pharmaceuticals Inc. Revenue by Segment — Quarterly Trend
Vanda Pharmaceuticals Inc. revenue by segment across the last 4 reported quarters, showing how each business line (such as Fanapt and Hetlioz) has evolved quarter over quarter.
| Segment | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 |
|---|---|---|---|---|
| Fanapt | $33.2M | $31.2M | $29.3M | $23.5M |
| Hetlioz | $16.4M | $18.0M | $16.2M | $20.9M |
| PONVORY | $7.6M | $7.0M | $7.1M | $5.6M |
Vanda Pharmaceuticals Inc. Annual Revenue by Year
Vanda Pharmaceuticals Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $216.1M).
Vanda Pharmaceuticals Inc. Quarterly Revenue & Net Profit History
Vanda Pharmaceuticals Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $57.2M | +7.6% | $-141.2M | -246.8% |
| Q3 FY2025 | $56.3M | +18.1% | $-22.6M | -40.1% |
| Q2 FY2025 | $52.6M | +4.2% | $-27.2M | -51.7% |
| Q1 FY2025 | $50.0M | +5.4% | $-29.5M | -58.9% |
| Q4 FY2024 | $53.2M | +17.5% | $-4.9M | -9.2% |
| Q3 FY2024 | $47.7M | +22.8% | $-5.3M | -11.2% |
| Q2 FY2024 | $50.5M | +9.6% | $-4.5M | -9.0% |
| Q1 FY2024 | $47.5M | -24.1% | $-4.1M | -8.7% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $47.5M | $50.5M | $47.7M | $53.2M | $50.0M | $52.6M | $56.3M | $57.2M |
| YoY Growth | -24.1% | 9.6% | 22.8% | 17.5% | 5.4% | 4.2% | 18.1% | 7.6% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $652.7M | $651.4M | $645.1M | $656.2M | $631.9M | $624.7M | $601.1M | $488.9M |
| Liabilities | $108.7M | $108.9M | $103.9M | $117.7M | $120.5M | $138.4M | $135.1M | $161.8M |
| Equity | $544.0M | $542.5M | $541.2M | $538.5M | $511.4M | $486.3M | $466.0M | $327.2M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $7.6M | $-6.9M | $-14.6M | $-1.8M | $-33.1M | $-15.3M | $-31.6M | $-29.4M |